Atlas Trials

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Clinical trial NCT05047991 · UNKNOWN

Trial details

NCT number
NCT05047991
Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Start date
2021-10-01
Primary completion
2023-11-01
Enrollment
153

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.